1. Home
  2. KHC vs UTHR Comparison

KHC vs UTHR Comparison

Compare KHC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Kraft Heinz Company

KHC

The Kraft Heinz Company

HOLD

Current Price

$21.84

Market Cap

28.5B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$528.29

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KHC
UTHR
Founded
1869
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.5B
23.9B
IPO Year
2015
1999

Fundamental Metrics

Financial Performance
Metric
KHC
UTHR
Price
$21.84
$528.29
Analyst Decision
Hold
Buy
Analyst Count
15
14
Target Price
$26.00
$531.79
AVG Volume (30 Days)
14.0M
485.2K
Earning Date
04-28-2026
04-29-2026
Dividend Yield
7.25%
N/A
EPS Growth
N/A
13.07
EPS
N/A
27.86
Revenue
$24,942,000,000.00
$1,483,300,000.00
Revenue This Year
N/A
$7.77
Revenue Next Year
$0.59
$11.11
P/E Ratio
N/A
$19.04
Revenue Growth
N/A
2.38
52 Week Low
$21.99
$266.98
52 Week High
$31.15
$548.12

Technical Indicators

Market Signals
Indicator
KHC
UTHR
Relative Strength Index (RSI) 30.53 57.52
Support Level N/A $464.92
Resistance Level $24.82 $542.66
Average True Range (ATR) 0.60 14.24
MACD -0.25 1.62
Stochastic Oscillator 3.04 74.46

Price Performance

Historical Comparison
KHC
UTHR

About KHC The Kraft Heinz Company

In July 2015, Kraft merged with Heinz to create one of North America's largest food and beverage manufacturers. Beyond its namesake brands, its portfolio includes Oscar Mayer, Velveeta, and Philadelphia. While the retail channel drives around 85% of its total sales, the firm also maintains a growing foodservice presence. Outside North America, Kraft Heinz's global reach encompasses a distribution network in Europe and emerging markets, which accounts for around 25% of its consolidated sales base. The company's products are sold in more than 190 countries and territories.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: